Page last updated: 2024-09-05

sb 203580 and razoxane

sb 203580 has been researched along with razoxane in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(razoxane)
Trials
(razoxane)
Recent Studies (post-2010) (razoxane)
3,48941,13782411556

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)razoxane (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 23.19

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Altieri, P; Ballestrero, A; Barisione, C; Barsotti, A; Brunelli, C; Fabbi, P; Garibaldi, S; Ghigliotti, G; Manca, V; Spallarossa, P1

Other Studies

1 other study(ies) available for sb 203580 and razoxane

ArticleYear
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.
    Cardiovascular research, 2006, Feb-15, Volume: 69, Issue:3

    Topics: Anthracenes; Antibiotics, Antineoplastic; Antioxidants; Blotting, Western; Carbazoles; Carvedilol; Catecholamines; Cell Line; Doxorubicin; Enzyme Activation; Flavonoids; Humans; Imidazoles; Imidazolines; Janus Kinase 1; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; NADPH Oxidases; p38 Mitogen-Activated Protein Kinases; Propanolamines; Protein-Tyrosine Kinases; Pyridines; Razoxane

2006